Table 1.
Clinical profiles and laboratory data of patients with HCC treated with lenvatinib
| Patient characteristics and laboratory data | |
| Number of patients | 56 |
| Gender, males: females, n | 40:16 |
| Age, years (range)a | 74 (45–91) |
| BMI, kg/m2 (range) | 22.3 (11.9−30.1) |
| Body weight <60 kg: ≥60 kg, n | 35: 21 |
| HCV:HBV:NonB, NonC, n | 30:6:20 |
| Performance status 0:1, n (%) | 53 (95): 3 (5) |
| Platelet count, ×103/µL (range)a | 132 (48–280) |
| Albumin, g/dL (range)a | 3.7 (3.0–4.5) |
| Total bilirubin, mg/dL (range)a | 1.0 (0.3–2.8) |
| Prothrombin activity, % (range)a | 82.8 (64.9–124.8) |
| AST, IU/L (range)a | 39.5 (15–351) |
| AFP, μg/L (range)a | 191.5 (0.8–61,040.7) |
| DCP, AU/L (range)a | 147.0 (13.0–63,347.0) |
| Child-Pugh score 5:6, n (%) | 34 (61):22 (39) |
| mALBI score (1:2a:2b:3), n (%) | 11 (20):24 (43):21 (38):0 (0) |
| Initial dose of lenvatinib, 4 mg:8 mg:12 mg, n (%) | 2 (4):31 (55):23 (41) |
| Reduced starting dose of lenvatinib, n (%) | 4 (7) |
| History of TKI treatment, n (%) | 4 (7) |
| Tumor characteristics | |
| Largest tumor diameter, mm (range)a | 31.4 (11.0–175.0) |
| Number of tumors, n (range) | 4 (1 to >200) |
| Macrovascular invasion, n (%) | 11 (20) |
| Extrahepatic metastasis, n (%) | 19 (34) |
| BCLC stage A:B:C, n (%) | 6 (11):25 (45):25 (45) |
| TACE failure/refractoriness, n (%) | 43 (77) |
| Pretreatment dynamic CT study enhancement pattern (number and ratio) | |
| Type-2 Type-3 Type-4, n (%) | 15 (27); 28 (50); 13 (23) |
The composition ratio is rounded off to the first decimal place and therefore the total will not necessarily be 100. AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; AST, aspartate aminotransferase; DCP, des-γ-carboxyprothrombin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IU, international units; mALBI, modified albumin-bilirubin; NonB, NonC, neither HBV nor HCV infection present; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor.
a
Data expressed as median (range).